Navigation Links
Cephalon Presents Positive Results for Fentora in Breakthrough Pain,,,Associated with Neuropathic Conditions

All Efficacy Measures Reached Statistical Significance

FRAZER, Pa., May 01, 2007 /PRNewswire-FirstCall/ -- A Cephalon, Inc. Phase 3 clinical trial presented today at the 59th Annual Meeting of the American Academy of Neurology in Boston highlights data demonstrating that FENTORA(R) (fentanyl buccal tablet) [C-II] is beneficial for the treatment of breakthrough pain in patients with neuropathic pain who are already taking opioids around-the clock to manage their persistent pain. This study marks the first time an opioid has been evaluated in patients with breakthrough pain associated with chronic neuropathic pain.

"This study provides strong evidence that opioids like FENTORA may be useful in managing breakthrough pain in patients with chronic neuropathic pain," said Dr. David Simpson, Professor of Neurology at Mount Sinai Medical Center and primary author of this study. "With FENTORA, patients experienced statistically significant and clinically meaningful improvements in pain control and expressed a preference for this medication over the opioid they had previously been prescribed to manage their breakthrough pain."

Breakthrough pain -- a component of chronic pain -- is a flare of moderate-to-severe pain that occurs in the context of controlled persistent pain and is characterized by rapid onset, moderate-to-severe intensity, and relatively short duration. An estimated 74 percent of patients with controlled persistent pain from noncancer chronic pain conditions, including neuropathic pain, will experience breakthrough pain with a median onset of 10 minutes. In this patient population, breakthrough pain episodes can typically last 60 minutes. FENTORA, which is approved for the management of breakthrough pain in patients with cancer who are already taking and who are tolerant to opioids for their underlying persistent cancer pain, is desig
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:4/17/2015)... DALLAS , April 17, 2015 ... report 2015 Market Research Report on Global and ... This is a professional and the deep ... the report introduces Lysine basic information including definition, ... overview (such as US, Europe ...
(Date:4/17/2015)... R.I , April 17, 2015 CVS ... a conference call on Friday, May 1, 2015, at ... its first quarter financial results. An audio ... through the Investor Relations portion of the CVS Health ... visit http://investors.cvshealth.com . This webcast will be archived ...
(Date:4/17/2015)... SAN DIEGO , April 17, 2015 /PRNewswire/ ... molecular diagnostics, announced today that clinical data presented ... demonstrate that its urine-based Precision Cancer Monitoring ℠ ... detection and monitoring of EGFR T790M ... titled Detection of EGFR T790M Mutation in ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
... The ALS Therapy Development Institute (ALS ... with Neurotune to investigate a potential treatment ... (Photo: http://photos.prnewswire.com/prnh/20120514/DC05793 ) ... health of motor neurons and their connections to muscles ...
... 2012  NxStage® Medical, Inc. (Nasdaq: NXTM ... today announced that former NxStage® System One™ patient ... transplant following four successful years of more frequent ... (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO ) The ...
Cached Medicine Technology:The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 3Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant 2Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant 3
(Date:4/18/2015)... 2015 Carinsurancesavings.biz has released a new ... are cheaper during Spring. , Spring can be ... Drivers should make sure they compare the newest policies ... can learn more about Spring car insurance offers by ... insurance quotes are becoming more and more popular. Many ...
(Date:4/18/2015)... SMITHTOWN, NEW YORK (PRWEB) April 18, 2015 ... Inc. (AMO) are hosting a ‘Strategies for Success’ program ... & Refractive Surgeons meeting in San Diego, where eye ... ‘Distinguished Moderator’ for this invitation-only event. Dr. Martin is ... AMO and Review of Ophthalmology chose Dr. Martin to ...
(Date:4/18/2015)... Patients who undergo radiation for a hematologic ... life, but the disease is likely to differ in ... radiation. Surviving Mesothelioma has just posted the details of ... to read it now. , Scientists from China, ... patients who had both a hematologic cancer (like lymphoma ...
(Date:4/18/2015)... On April 14th, 2015, Symantec released Volume ... say, “exposes a tactical shift by cyberattackers.” With everything from ... in 2014 - almost a million a day - to ... identified and patched by prominent manufacturers – as long as ... in a digital world can be fraught with peril, and ...
(Date:4/18/2015)... 2015 French physician and gastronome Anthelme ... when he uttered, “Tell me what you eat, and ... to cope with stress or sadness has often been ... indicates otherwise. Data collected from their Emotional Eating ... emotional eating, but for different reasons. , Collecting data ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6
... given the same procedure by an average of 4.5 years, ... ,And while younger people tend to live longest of ... life compared with those who have not had liver transplants, ... life expectancy and years of life lost of 2702 people ...
... performed by physicians experienced with the technique//, and pain ... one-year, multi-center cohort study. ,Among the 25 patients ... on a 10-point visual analog scale was 7.3 at ... at 24 weeks, and 0.3 at 52 weeks, according ...
... for treating patients with advanced colorectal cancer has been approved ... other parts of the body.//Panitumamab, which is being marketed as ... size and retard cancer cell growth. ,The approval has ... which has a high mortality rate. Colorectal cancer has been ...
... women after consumption of raw oysters. Further probing revealed that ... ,Agriculture Commissioner Tommy Irvin commenting on the deaths said “The ... and they lost their lives.” In his opinion, raw oysters ... DeKalb Farmers’ Market reiterated that they have always been enabling ...
... Recent studies conducted by Yale School Of Medicine have ... androgens or steroids to enhance muscle mass or for ... in the body can lead to a appalling loss ... steroids was previously proven to cause hyper excitability, volatile ...
... is the most notorious of cancers, going by the United Kingdom ... of three cases happens to be of the breast. , ... increase in cancer. The present record for breast cancer is 36,939 ... cancer is up since 1971 by almost 81%. ...
Cached Medicine News:Health News:Sacroplasty Safe and Effective to Reduce Low Back Pain 2Health News:Sacroplasty Safe and Effective to Reduce Low Back Pain 3Health News:FDA Approves Vectibix for Colorectal Cancer 2
... fast and effective resection of meniscal tears ... rim. The flat, crescent-shaped tip has an ... tightest joint spaces. Made in the U.S. ... engineering experience in arthroscopy hand instrument design ...
... Punch series facilitates fast and effective resection ... anatomically shaped meniscal rim. The flat, crescent-shaped ... access even the tightest joint spaces. Made ... 20 years of engineering experience in arthroscopy ...
... provides fingertip ratchet disengagement allowing smooth, ratchet-free ... offers state-of-the-art quality in an instrument of ... durability. Low profile cutting tips allow access ... I instruments are available in just about ...
... The patented ratchet design provides fingertip ratchet ... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ...
Medicine Products: